The duty to disclose adverse clinical trial results.
Participants in some clinical trials are at risk of being harmed and sometimes are seriously harmed as a result of not being provided with available, relevant risk information. We argue that this situation is unacceptable and that there is a moral duty to disclose all adverse clinical trial results...
主要な著者: | Liao, S, Sheehan, M, Clarke, S |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2009
|
類似資料
-
Disclosing clinical trial results: publicity, significance and independence.
著者:: Liao, S, 等
出版事項: (2009) -
Randomization should be disclosed to potential research subjects.
著者:: Binik, A, 等
出版事項: (2013) -
Comparative Study of Securities issuer's affirmative duty to disclose information
in Iranian and American Law
著者:: Morteza Shahidi, 等
出版事項: (2020-04-01) -
Press releases for Phase 2 clinical trial topline results: Have the objective pre-specified efficacy results been disclosed?
著者:: Zheng Su, 等
出版事項: (2016-12-01) -
HIV/AIDS, TO DISCLOSE OR NOT TO DISCLOSE: THAT IS THE QUESTION
著者:: Andra le Roux-Kemp
出版事項: (2013-04-01)